Division of Colfax Corp.
Latest From Exos Corp.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.
- Medical Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Colfax Corp.
- Senior Management
Fariborz Boor Boor, Pres. & CEO
Mark Joseph, CTO
Douglas King, VP, Sales
Brian Bowen, VP, Strategic Mktg. & Bus. Dev.
- Contact Info
Phone: (866) 773-0539
1122 Red Fox Rd.
Arden Hills, MN 55112
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.